[
  {
    "question": "Case scenario of a patient with urinary urgency, gait problem, memory problems, MRI showed very extensive white matter lesions asked about dx?",
    "option_a": "NPH",
    "option_b": "Binswanger",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "The case presents a triad of urinary urgency, gait disturbance, and cognitive impairment. Differentiation between similar presenting syndromes relies on imaging findings, particularly the pattern of white matter involvement. Binswanger disease, a form of subcortical vascular dementia, results from chronic hypertension or other vascular risk factors leading to small vessel disease and extensive demyelination in the cerebral white matter. This white matter damage disrupts neural connectivity and results in cognitive and motor deficits. Clinically, patients with Binswanger disease may present with executive dysfunction, slowed processing speed, gait abnormalities, and urinary incontinence. These symptoms are the result of subcortical ischemic changes rather than hydrocephalus. MRI is instrumental in differentiating Binswanger disease from normal pressure hydrocephalus (NPH). Binswanger disease is characterized by extensive, confluent white matter hyperintensities, while NPH is typically associated with ventriculomegaly out of proportion to cortical atrophy. Differential diagnoses include Alzheimer\u2019s disease (primarily cortical atrophy) and other causes of vascular dementia. Management focuses on addressing vascular risk factors (e.g., hypertension, diabetes, hyperlipidemia) through medical therapy and lifestyle modifications. There is no disease-specific approved treatment; therapeutic strategies aim to slow progression. Although pregnancy and lactation considerations are uncommon in this typically older population, managing vascular risk in younger patients should also consider the safety profile of antihypertensive and antiplatelet agents. Option A (NPH) is less appropriate because NPH is mainly characterized by ventricular enlargement on imaging rather than widespread white matter lesions. Option B (Binswanger) correctly aligns with the extensive white matter changes and the patient\u2019s clinical presentation. 1) Extensive white matter hyperintensities on MRI in a patient with gait and urinary disturbances point towards a vascular etiology like Binswanger disease. 2) Managing underlying vascular risk factors is essential in halting progression of vascular dementia. Recent research reinforces the role of rigorous control of vascular risk factors in patients with subcortical ischemic changes. Advanced neuroimaging and the use of standardized criteria help differentiate Binswanger disease from other causes of cognitive impairment.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with young onset familial Alzheimer's with family hx. What is the gene?",
    "option_a": "APP",
    "option_b": "NO PSEN1 or 2",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Early-onset familial Alzheimer\u2019s disease (EOFAD) is a genetically inherited form of Alzheimer\u2019s that typically presents before the age of 65. Key genes implicated include APP, PSEN1, and PSEN2, all of which follow an autosomal dominant inheritance pattern. Mutations in these genes lead to abnormal processing of amyloid precursor protein (APP) and subsequent accumulation of the amyloid-beta peptide, which forms plaques that disrupt neuronal function. PSEN1 mutations, in particular, account for the majority of EOFAD cases, but APP mutations are also well recognized. Patients with EOFAD usually present with progressive memory impairment and other cognitive deficits at a young age relative to typical sporadic Alzheimer\u2019s disease. A positive family history is a strong indicator of a genetic cause. A comprehensive evaluation including detailed family history, neuropsychological testing, and genetic counseling is indicated. Genetic testing can identify mutations in APP, PSEN1, or PSEN2. Differential diagnoses include other forms of dementia and metabolic or infectious causes of early cognitive decline. Management involves supportive care, early initiation of approved Alzheimer's medications (such as cholinesterase inhibitors and memantine when appropriate), and rigorous genetic counseling for family members. Although pregnancy and lactation are not typical concerns in EOFAD patients, any pharmacologic therapy in women of childbearing potential should be approached with caution, ensuring risk-benefit analysis in the context of current guidelines. Option A (APP) is a recognized gene associated with familial Alzheimer\u2019s disease, although it is not the most common (PSEN1 mutations are more frequently implicated). Option B (NO PSEN1 or 2) is incorrect because it erroneously dismisses two major genes known to cause EOFAD. Given the available options, the correct response is Option A. 1) PSEN1 is the most common mutation in EOFAD, but APP mutations are also implicated. 2) Autosomal dominant patterns in Alzheimer\u2019s should prompt consideration of genetic counseling for family members. Recent studies have further elucidated the molecular mechanisms by which APP processing is altered in EOFAD. Genetic screening and counseling are increasingly recommended for early-onset cases, and ongoing research focuses on targeted therapies that may modify disease progression in genetically predisposed individuals.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "70 years old man was brought by his son due to a history of forgetting his keys, difficulty with remembering his appointment. No behavioral issues, no depressive symptoms. Patient is fully independent and able to his day-to-day activity without help (age related MCI)",
    "option_a": "reassure",
    "option_b": "Start Memantine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is recognized by minimal cognitive deficits that do not interfere significantly with daily activities. This patient\u2019s preserved independence in day-to-day functioning is a hallmark of MCI rather than full-blown dementia. MCI can represent an intermediate stage in the continuum between normal aging and Alzheimer\u2019s dementia. It may involve subtle neuronal changes without widespread neurodegeneration that affects everyday functioning. The patient presents with minor memory lapses such as forgetting keys and appointments, but still retains full capacity in his activities of daily living. There are no significant behavioral changes or depressive symptoms, supporting a diagnosis of MCI. Evaluation typically involves cognitive screening tests like the MoCA or MMSE, detailed history, and assessment for functional impairments. Differential diagnoses include early Alzheimer\u2019s disease, age-associated memory impairment, and depression (pseudodementia). The current management of MCI emphasizes monitoring and lifestyle modifications, including regular cognitive exercises and cardiovascular risk management. Pharmacologic treatments such as cholinesterase inhibitors or memantine are not indicated in MCI. For women who might be pregnant or lactating (though generally not applicable in this elderly population), any medication would require careful consideration of potential risks, making non-pharmacologic management preferable. Option A (reassure) is correct as it aligns with the management of MCI, which involves observation, cognitive monitoring, and lifestyle interventions. Option B (Start Memantine) is inappropriate because memantine is approved for moderate to severe Alzheimer\u2019s dementia and is not indicated for MCI. 1) MCI is characterized by memory lapses without significant impairments in daily living. 2) Regular follow-up is important because MCI can sometimes progress to Alzheimer\u2019s disease. Recent guidelines stress the importance of non-pharmacologic strategies in managing MCI, and research continues to explore biomarkers that predict progression to Alzheimer\u2019s disease. The emphasis remains on lifestyle interventions and cognitive training rather than early pharmacotherapy.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Cbd case what is in Pet scan?",
    "option_a": "Asymmetrical hypometabolism in tempo-partial",
    "option_b": "Hypometabolism in precenttal and post central association cortex with asymmetry within the same hemisphere",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal degeneration (CBD) is a neurodegenerative tauopathy characterized by asymmetrical involvement of the cerebral cortex. It typically presents with unilateral motor deficits along with higher cortical dysfunctions such as apraxia and alien limb phenomenon. CBD involves abnormal accumulation of hyperphosphorylated tau protein which leads to progressive neuronal degeneration predominantly in the motor and sensory cortices. This pathology results in diminished glucose metabolism on FDG-PET imaging. The degenerative process is usually more pronounced in the precentral (motor) and postcentral (sensory) regions of one hemisphere rather than the temporoparietal areas, which are more commonly involved in Alzheimer\u2019s disease. Patients with CBD often exhibit marked asymmetry in motor impairment, difficulty with complex movements (apraxia), and sometimes language and cognitive deficits. The asymmetric PET findings correlate directly with the side of clinical manifestations. The differential diagnosis includes Alzheimer\u2019s disease (which typically shows temporoparietal hypometabolism), Parkinson\u2019s disease, and other atypical parkinsonian syndromes. FDG-PET is a key imaging modality that helps differentiate these conditions by identifying specific patterns of regional hypometabolism. There is currently no disease-modifying treatment for CBD. Management is symptomatic and multidisciplinary, focusing on physical, occupational, and speech therapy. Medications such as levodopa may be tried with limited benefit. In pregnant or lactating women, most pharmacologic interventions are used with caution; nonpharmacological and supportive treatments are preferred due to the potential risks of dopaminergic agents. Option A, which describes asymmetrical hypometabolism in the temporoparietal region, is more typical of Alzheimer\u2019s disease. Option B correctly identifies the pattern seen in CBD\u2014hypometabolism in the precentral and postcentral cortices with asymmetry within one hemisphere. 1. FDG-PET scans in CBD characteristically show unilateral hypometabolism affecting sensorimotor areas. 2. The clinical asymmetry in motor deficits correlates with the imaging findings in CBD. Recent studies reinforce the role of FDG-PET as a supportive biomarker for CBD, emphasizing the distinct metabolic pattern compared to other neurodegenerative disorders. Ongoing research aims to identify disease-modifying therapies, but current management remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Description of pathology not picture (aquabin and alpha syncilin):",
    "option_a": "pick disease",
    "option_b": "Lewy body",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal degeneration (CBD) is a neurodegenerative tauopathy characterized by asymmetrical involvement of the cerebral cortex. It typically presents with unilateral motor deficits along with higher cortical dysfunctions such as apraxia and alien limb phenomenon. CBD involves abnormal accumulation of hyperphosphorylated tau protein which leads to progressive neuronal degeneration predominantly in the motor and sensory cortices. This pathology results in diminished glucose metabolism on FDG-PET imaging. The degenerative process is usually more pronounced in the precentral (motor) and postcentral (sensory) regions of one hemisphere rather than the temporoparietal areas, which are more commonly involved in Alzheimer\u2019s disease. Patients with CBD often exhibit marked asymmetry in motor impairment, difficulty with complex movements (apraxia), and sometimes language and cognitive deficits. The asymmetric PET findings correlate directly with the side of clinical manifestations. The differential diagnosis includes Alzheimer\u2019s disease (which typically shows temporoparietal hypometabolism), Parkinson\u2019s disease, and other atypical parkinsonian syndromes. FDG-PET is a key imaging modality that helps differentiate these conditions by identifying specific patterns of regional hypometabolism. There is currently no disease-modifying treatment for CBD. Management is symptomatic and multidisciplinary, focusing on physical, occupational, and speech therapy. Medications such as levodopa may be tried with limited benefit. In pregnant or lactating women, most pharmacologic interventions are used with caution; nonpharmacological and supportive treatments are preferred due to the potential risks of dopaminergic agents. Option A, which describes asymmetrical hypometabolism in the temporoparietal region, is more typical of Alzheimer\u2019s disease. Option B correctly identifies the pattern seen in CBD\u2014hypometabolism in the precentral and postcentral cortices with asymmetry within one hemisphere. 1. FDG-PET scans in CBD characteristically show unilateral hypometabolism affecting sensorimotor areas. 2. The clinical asymmetry in motor deficits correlates with the imaging findings in CBD. Recent studies reinforce the role of FDG-PET as a supportive biomarker for CBD, emphasizing the distinct metabolic pattern compared to other neurodegenerative disorders. Ongoing research aims to identify disease-modifying therapies, but current management remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Alzheimer pt presented with depression symptoms (sadness, insomnia) and agitation what you will give:",
    "option_a": "Cipralex",
    "option_b": "Trazadone",
    "option_c": "Quatipin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal degeneration (CBD) is a neurodegenerative tauopathy characterized by asymmetrical involvement of the cerebral cortex. It typically presents with unilateral motor deficits along with higher cortical dysfunctions such as apraxia and alien limb phenomenon. CBD involves abnormal accumulation of hyperphosphorylated tau protein which leads to progressive neuronal degeneration predominantly in the motor and sensory cortices. This pathology results in diminished glucose metabolism on FDG-PET imaging. The degenerative process is usually more pronounced in the precentral (motor) and postcentral (sensory) regions of one hemisphere rather than the temporoparietal areas, which are more commonly involved in Alzheimer\u2019s disease. Patients with CBD often exhibit marked asymmetry in motor impairment, difficulty with complex movements (apraxia), and sometimes language and cognitive deficits. The asymmetric PET findings correlate directly with the side of clinical manifestations. The differential diagnosis includes Alzheimer\u2019s disease (which typically shows temporoparietal hypometabolism), Parkinson\u2019s disease, and other atypical parkinsonian syndromes. FDG-PET is a key imaging modality that helps differentiate these conditions by identifying specific patterns of regional hypometabolism. There is currently no disease-modifying treatment for CBD. Management is symptomatic and multidisciplinary, focusing on physical, occupational, and speech therapy. Medications such as levodopa may be tried with limited benefit. In pregnant or lactating women, most pharmacologic interventions are used with caution; nonpharmacological and supportive treatments are preferred due to the potential risks of dopaminergic agents. Option A, which describes asymmetrical hypometabolism in the temporoparietal region, is more typical of Alzheimer\u2019s disease. Option B correctly identifies the pattern seen in CBD\u2014hypometabolism in the precentral and postcentral cortices with asymmetry within one hemisphere. 1. FDG-PET scans in CBD characteristically show unilateral hypometabolism affecting sensorimotor areas. 2. The clinical asymmetry in motor deficits correlates with the imaging findings in CBD. Recent studies reinforce the role of FDG-PET as a supportive biomarker for CBD, emphasizing the distinct metabolic pattern compared to other neurodegenerative disorders. Ongoing research aims to identify disease-modifying therapies, but current management remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about HC asking about dx",
    "option_a": "HC",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal degeneration (CBD) is a neurodegenerative tauopathy characterized by asymmetrical involvement of the cerebral cortex. It typically presents with unilateral motor deficits along with higher cortical dysfunctions such as apraxia and alien limb phenomenon. CBD involves abnormal accumulation of hyperphosphorylated tau protein which leads to progressive neuronal degeneration predominantly in the motor and sensory cortices. This pathology results in diminished glucose metabolism on FDG-PET imaging. The degenerative process is usually more pronounced in the precentral (motor) and postcentral (sensory) regions of one hemisphere rather than the temporoparietal areas, which are more commonly involved in Alzheimer\u2019s disease. Patients with CBD often exhibit marked asymmetry in motor impairment, difficulty with complex movements (apraxia), and sometimes language and cognitive deficits. The asymmetric PET findings correlate directly with the side of clinical manifestations. The differential diagnosis includes Alzheimer\u2019s disease (which typically shows temporoparietal hypometabolism), Parkinson\u2019s disease, and other atypical parkinsonian syndromes. FDG-PET is a key imaging modality that helps differentiate these conditions by identifying specific patterns of regional hypometabolism. There is currently no disease-modifying treatment for CBD. Management is symptomatic and multidisciplinary, focusing on physical, occupational, and speech therapy. Medications such as levodopa may be tried with limited benefit. In pregnant or lactating women, most pharmacologic interventions are used with caution; nonpharmacological and supportive treatments are preferred due to the potential risks of dopaminergic agents. Option A, which describes asymmetrical hypometabolism in the temporoparietal region, is more typical of Alzheimer\u2019s disease. Option B correctly identifies the pattern seen in CBD\u2014hypometabolism in the precentral and postcentral cortices with asymmetry within one hemisphere. 1. FDG-PET scans in CBD characteristically show unilateral hypometabolism affecting sensorimotor areas. 2. The clinical asymmetry in motor deficits correlates with the imaging findings in CBD. Recent studies reinforce the role of FDG-PET as a supportive biomarker for CBD, emphasizing the distinct metabolic pattern compared to other neurodegenerative disorders. Ongoing research aims to identify disease-modifying therapies, but current management remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "In MMSE what carry high weight",
    "option_a": "orientation",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The Mini Mental State Examination (MMSE) is a widely used screening tool for cognitive impairment. It tests multiple domains of cognition including orientation, registration, attention/calculation, recall, language, and visuospatial skills. Among these, orientation (assessing awareness of time and place) carries the highest point value (10 points out of 30) and is thus heavily weighted in the overall score. MMSE scores reflect the underlying integrity of various cognitive domains. In patients with neurodegenerative conditions like Alzheimer\u2019s disease, deficits in orientation are common due to dysfunction in brain regions responsible for memory and executive functions. The heavy weighting of orientation makes the MMSE sensitive to early cognitive decline in disorders that alter these neural networks. Impairment in orientation is often one of the earliest signs of global cognitive dysfunction. Clinically, patients who become disoriented when asked about the current date or location may be manifesting early signs of dementia. This aspect of the MMSE is crucial in distinguishing normal aging from pathologic cognitive decline. When evaluating cognitive impairment, clinicians should consider a range of differential diagnoses including Alzheimer\u2019s disease, vascular dementia, frontotemporal dementia, and delirium. The MMSE is used alongside detailed history, physical examination, and laboratory/imaging studies to contribute to the overall clinical picture. While the MMSE itself is not a treatment tool, it helps gauge disease severity which is critical for management decisions in conditions like Alzheimer\u2019s disease. Overall management of dementia typically involves pharmacological therapies (e.g., cholinesterase inhibitors, memantine) and non-pharmacological strategies including cognitive therapy and lifestyle modifications. In pregnant or lactating patients, nonpharmacologic interventions are preferred and any use of medications must be carefully evaluated for risk-benefit profiles. Option A (Orientation) is correct because it carries a weight of 10 points in the MMSE, more than any other domain. The other options were left blank, and with no competing alternatives the emphasis on orientation is appropriate based on the test\u2019s structure. 1. Orientation contributes 10 points to the total MMSE score, making it a key part of the exam. 2. A decline in orientation may be an early indicator of dementia. 3. The MMSE is a useful tool for serial cognitive assessments over time. Recent updates and research continue to validate the MMSE as a practical screening tool despite its limitations in detecting executive dysfunction. While newer tools and digital assessments are emerging, the MMSE remains widely used in both clinical and research settings for initial cognitive screening.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What suggest AD not LBD",
    "option_a": "Sleep disorder",
    "option_b": "Shuffling gait",
    "option_c": "Brain atrophy",
    "option_d": "Anterograde memory impairment",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) and Lewy Body Dementia (LBD) can present with overlapping cognitive symptoms. However, the pattern of cognitive deficits differs, with AD classically presenting with early anterograde memory impairment, particularly difficulty forming new memories, while LBD is often characterized by fluctuating cognition along with visual hallucinations and parkinsonian features. AD is primarily a neurodegenerative disorder marked by beta-amyloid plaques and neurofibrillary tangles, predominantly affecting the medial temporal lobe structures including the hippocampus, which are critical for memory formation. LBD, on the other hand, is characterized by alpha-synuclein deposits (Lewy bodies) that affect cortical and subcortical regions, accounting for its distinct features such as parkinsonism and sleep disturbances. Patients with AD typically have marked difficulties with new memory formation (anterograde memory impairment). In contrast, patients with LBD may show less prominent memory issues initially but will display visual hallucinations, REM sleep behavior disorder, and parkinsonian motor signs. This difference in early clinical presentation helps in differentiating the two conditions. Differential diagnoses include AD, LBD, vascular dementia, and frontotemporal dementia. Neuropsychological testing often reveals a prominent memory deficit in AD, while LBD may show variability in attention and visuospatial skills. Brain imaging (MRI, FDG-PET) can also aid by demonstrating medial temporal lobe atrophy in AD versus less pronounced atrophy in LBD. For AD, first-line management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine in moderate to severe stages. Non-pharmacological strategies such as cognitive rehabilitation and lifestyle modifications are also crucial. In pregnancy and lactation, the safety profile of cholinesterase inhibitors is not well established, so non-pharmacological interventions tend to be preferred and treatment is generally deferred unless clearly indicated. Option D (Anterograde memory impairment) is correct because it is the hallmark early deficit in AD. Options A (Sleep disorder) and B (Shuffling gait) are commonly seen in LBD due to its association with REM sleep disturbances and parkinsonian signs. Option C (Brain atrophy) is non-specific and can be seen in both AD and LBD, making it less useful for differentiation. 1. Early anterograde memory loss is a classic feature of AD. 2. Fluctuating cognition, visual hallucinations, and parkinsonism point towards LBD. 3. Neuroimaging and neuropsychological testing are key in differentiating these dementias. Current diagnostic criteria and guidelines, such as those from the National Institute on Aging-Alzheimer\u2019s Association, emphasize the importance of memory impairment in AD. Recent advances in biomarkers and imaging techniques further enhance the ability to differentiate AD from LBD in clinical practice.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Imaging finding of CBD",
    "option_a": ", which indicates 'Temporal and parietal association involvement', is considered correct in this context. This option reflects the imaging findings of asymmetric hypometabolism and cortical atrophy in CBD. Other potential options such as isolated primary motor cortex involvement, predominant frontal atrophy, occipital lobe changes, or exclusive subcortical involvement are less characteristic of CBD and more typical of other neurodegenerative disorders.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal degeneration (CBD) is a rare, progressive neurodegenerative disease characterized by asymmetric motor and cognitive dysfunction. Imaging plays an important role in supporting the diagnosis by revealing patterns of cerebral atrophy and hypometabolism. CBD is a tauopathy in which abnormal accumulation of the tau protein results in neuronal loss and gliosis. This pathology tends to be asymmetric and predominantly affects the cortical association areas, particularly those in the parietal lobe; involvement may extend to temporal association cortices in some cases. The asymmetry and specific regional atrophy correlate with clinical findings such as apraxia and rigidity. Clinically, CBD patients often present with asymmetric motor deficits (e.g., limb apraxia, dystonia, or rigidity) and cognitive disturbances, including problems with planning and visuospatial functions. The imaging findings of asymmetric atrophy in the parietal (and sometimes temporal) association regions help corroborate the clinical suspicion. The differential diagnosis includes progressive supranuclear palsy (PSP), frontotemporal dementia, and atypical parkinsonian syndromes. MRI and FDG-PET imaging help differentiate these conditions; for instance, PSP typically shows midbrain atrophy, while frontotemporal dementia involves pronounced frontal and/or temporal atrophy. The pattern of asymmetric parietal and temporal association involvement is more characteristic of CBD. There is currently no disease-modifying treatment available for CBD. Management focuses on symptomatic relief and supportive care, including physical, occupational, and speech therapy. Medications such as levodopa may be trialed for motor symptoms, but responses are often limited. In the context of pregnancy and lactation, treatment is tailored toward nonpharmacologic interventions due to the limited safety data on many drugs used for neurodegenerative conditions, although CBD predominantly affects older adults. Option A, which indicates 'Temporal and parietal association involvement', is considered correct in this context. This option reflects the imaging findings of asymmetric hypometabolism and cortical atrophy in CBD. Other potential options such as isolated primary motor cortex involvement, predominant frontal atrophy, occipital lobe changes, or exclusive subcortical involvement are less characteristic of CBD and more typical of other neurodegenerative disorders. 1. CBD often presents with marked asymmetry in motor and cognitive symptoms. 2. Imaging typically reveals asymmetric atrophy, especially in the parietal cortex, with possible extension into temporal association areas. 3. The response to dopaminergic therapy is generally poor in CBD, distinguishing it from other parkinsonian syndromes. Recent research, including advanced imaging modalities like tau PET scanning, continues to refine our understanding of CBD\u2019s pathology. While conventional MRI and FDG-PET remain cornerstones for diagnosis, these newer imaging techniques may soon play a larger role in differentiating CBD from other tauopathies and atypical parkinsonian disorders.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "MCI tx",
    "option_a": "Life style change",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is a clinical state characterized by cognitive decline greater than expected for an individual\u2019s age and education level but not severe enough to interfere significantly with daily functioning or meet the criteria for dementia. It represents a risk state for progression to Alzheimer\u2019s disease but is also reversible in some instances. The underlying mechanisms in MCI are varied and may include early neurodegenerative changes, vascular pathology, or multifactorial age-related brain changes. In some patients, MCI represents the early stages of Alzheimer\u2019s disease with subtle accumulation of beta-amyloid plaques and tau pathology, whereas in others, it may be due to modifiable vascular risk factors or even normal aging. Clinically, individuals with MCI may experience subjective memory complaints and challenges in cognitive tasks, yet they typically maintain independence in their daily activities. These patients require close monitoring since a significant proportion can progress to dementia over time. The evaluation of MCI involves detailed neuropsychological testing, clinical history, and sometimes neuroimaging to rule out other conditions such as depression (pseudodementia) or early dementia. Differential diagnoses include normal age-related cognitive decline, depression, and early dementia such as Alzheimer\u2019s disease. First-line management for MCI centers on non-pharmacological approaches. Lifestyle modifications, including regular physical activity, cognitive training, social engagement, and dietary adjustments (e.g., adherence to a Mediterranean diet), are recommended. Management of vascular risk factors (hypertension, diabetes, hyperlipidemia) is also essential. Pharmacologic treatments, such as cholinesterase inhibitors, have not consistently proven effective in MCI and are not routinely recommended. In pregnancy and lactation, non-pharmacological approaches are safest and preferred since there is no established or approved medication for MCI in these populations. Option A (Lifestyle change) is correct because current guidelines and evidence support lifestyle modifications as the mainstay of treatment for MCI. Given the multifactorial and potentially reversible nature of MCI, interventions such as exercise, cognitive engagement, and risk factor optimization are emphasized over pharmacological treatments. 1. Lifestyle interventions are the cornerstone of MCI management. 2. MCI does not necessarily progress to dementia, and early intervention can delay progression. 3. Regular monitoring and neuropsychological assessments are important to track cognitive changes over time. Recent studies, including the FINGER trial, have demonstrated that multidomain lifestyle interventions can improve or stabilize cognitive function in individuals with MCI. While research continues to explore pharmacologic avenues, lifestyle modification remains the recommended first-line approach in current clinical guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "MCI what will change disease course",
    "option_a": "Vit E",
    "option_b": "Rivastigmine",
    "option_c": "Solanezumab",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is a clinical syndrome characterized by a measurable decline in cognitive function greater than expected for age, but not severe enough to interfere significantly with daily life or independent function. The concept of a disease\u2010modifying therapy implies an intervention that changes the underlying disease process rather than just treating symptoms. The underlying pathology in MCI\u2014especially when it is a prodromal stage of Alzheimer\u2019s disease (AD)\u2014involves early amyloid deposition, tau protein accumulation, synaptic dysfunction, and neuronal loss. Although therapies targeting amyloid (anti\u2010amyloid monoclonal antibodies such as solanezumab) were developed with the goal of altering this cascade, robust phase III clinical trial results have not shown a significant impact on disease progression. Clinically, patients with MCI may present with memory disturbances and subtle changes in other cognitive domains. Despite the promising mechanism of anti\u2010amyloid therapies, real\u2010world clinical outcomes have demonstrated that no pharmacologic intervention conclusively alters the long\u2010term trajectory of MCI progression to dementia. When evaluating MCI, the differential includes normal aging, mild neurocognitive disorder due to medical conditions, vascular cognitive impairment, and early Alzheimer\u2019s disease. Diagnosis relies on neuropsychological testing, sometimes coupled with imaging (MRI or PET), and the use of cerebrospinal fluid (CSF) biomarkers in select cases. The differentiation is made by considering the severity of cognitive deficits, functional impact, and supportive biomarker findings. Current management of MCI is focused on risk factor modification, lifestyle interventions (such as physical exercise, cognitive training, and diet optimization), and close monitoring for progression. None of the agents listed (Vitamin E, Rivastigmine, Solanezumab) has evidence strong enough to recommend routine use for changing the disease course. In pregnancy and lactation, non\u2010pharmacologic interventions remain the mainstay, as none of these drugs are indicated or approved for use in these populations. Option A (Vitamin E) has been explored for its antioxidant properties but lacks clear evidence in modifying disease progression. Option B (Rivastigmine) is a cholinesterase inhibitor that can provide symptomatic benefit in AD but does not alter underlying pathology. Option C (Solanezumab) is an anti\u2010amyloid monoclonal antibody developed to be disease modifying; however, large phase III trials have not demonstrated a definitive impact on MCI progression. Option D, assumed to represent \u201cNone of the above,\u201d is the best answer in light of current evidence. 1. No approved pharmacologic agent has been shown to alter the course of MCI. 2. Disease modification remains an unmet need in early Alzheimer\u2019s disease and pre\u2010dementia stages. 3. Lifestyle and vascular risk management are the mainstays of MCI management. Recent reviews and guidelines emphasize that while several agents (especially anti\u2010amyloid therapies) have been explored as disease modifiers, none have conclusively demonstrated a clinical benefit in altering the progression of MCI. The focus remains on non\u2010pharmacologic interventions and risk factor management.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "AD clinical but pet scan normal next",
    "option_a": "Low 42 amyloid, high phost tau",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is diagnosed based on clinical assessments along with supportive biomarkers. When imaging (such as PET scans) is inconclusive or normal despite a clinical picture suggestive of AD, additional biomarker evaluation can be very useful. AD pathology is defined by the deposition of beta-amyloid plaques and the formation of neurofibrillary tangles composed of hyperphosphorylated tau protein. In the cerebrospinal fluid (CSF), amyloid-\u03b2 42 levels are reduced as the peptide becomes sequestered within plaques, while phosphorylated tau levels are elevated due to neuronal injury and tangle formation. A patient with a clinical syndrome suggestive of AD but a normal PET scan may be in a stage where the PET imaging is less sensitive or the pathology is not yet extensive; CSF studies can often detect biomarker changes (i.e., low A\u03b242 with high phospho-tau) that correlate with AD and help in making the diagnosis. The diagnostic evaluation in suspected AD includes neuropsychological testing, structural imaging (MRI), and when needed, molecular imaging (amyloid PET). In cases of diagnostic uncertainty, CSF analysis is recommended. Differential diagnoses include other dementias such as frontotemporal dementia, vascular dementia, and Lewy body dementia, each of which has its own characteristic imaging and CSF profiles. Management of AD involves symptomatic treatments (cholinesterase inhibitors and NMDA receptor antagonists) and, in some jurisdictions, the cautious use of recently developed amyloid-targeting agents for early-stage disease. In pregnancy and lactation, none of these therapies is typically indicated; supportive care and non-pharmacologic management are emphasized. Option A (Low A\u03b242, high phospho-tau) correctly describes the CSF biomarker profile in Alzheimer\u2019s disease. Other options (not provided) would not align with the expected pathophysiologic changes in AD when imaging is normal. 1. CSF biomarker evaluation can be a useful adjunct in AD diagnosis when imaging studies are inconclusive. 2. The typical AD CSF profile shows low amyloid-\u03b2 42 and high phosphorylated tau levels. 3. The AT(N) framework has become central to the modern understanding of AD pathology. Recent guidelines and research support the integration of CSF biomarkers and the AT(N) framework into the diagnostic criteria for AD. Even when PET imaging is normal, these biomarkers can help confirm the biochemical presence of AD pathology.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Behavioral variant FTD normal semantic and language what is the pathology",
    "option_a": "TDP-43",
    "option_b": "FTD type A TDP",
    "option_c": "FTD type B TDP",
    "option_d": "FTD type C TDP",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) is an umbrella term for a group of neurodegenerative disorders that predominantly affect the frontal and temporal lobes. The behavioral variant FTD (bvFTD) is characterized primarily by changes in personality, behavior, and executive function while language and semantic memory may be preserved. A substantial proportion of FTD cases are associated with TDP-43 proteinopathy. Neuropathologically, FTLD-TDP is classified into subtypes (Type A, B, and C) based on the morphology and distribution of TDP-43 positive inclusions. FTLD-TDP Type B is typically associated with the behavioral variant, particularly in association with C9orf72 genetic expansions, and is characterized by a relatively uniform distribution of neuronal cytoplasmic inclusions. In bvFTD with preserved language and semantics, one expects predominant behavioral changes (disinhibition, apathy, compulsivity) without the marked language deficits seen in the semantic variant of FTD, which is more commonly linked with FTLD-TDP Type C pathology. The diagnosis of bvFTD is clinical, supported by neuropsychological evaluation and imaging (MRI or FDG-PET) that usually reveals frontal and/or anterior temporal lobe atrophy or hypometabolism. Differential diagnoses include psychiatric disorders, Alzheimer\u2019s disease, and vascular dementia. Biomarker or genetic studies (e.g., for C9orf72 expansions) can further support the diagnosis. There is no proven disease-modifying treatment for FTD; management is mainly supportive and symptomatic. Behavioral symptoms may be managed with selective serotonin reuptake inhibitors (SSRIs) or other psychiatric medications, and caregiver support is essential. In patients of childbearing potential, caution is warranted with psychotropic use; nonpharmacologic therapies are preferred during pregnancy and lactation when possible. \u2022 Option A (simply 'TDP-43') is nonspecific and does not distinguish among the subtypes. \u2022 Option B (FTD Type A TDP) is more frequently associated with language deficits and GRN mutations. \u2022 Option C (FTD Type B TDP) best fits the scenario of a behavioral variant FTD with preserved language, often linked to C9orf72. \u2022 Option D (FTD Type C TDP) is typically associated with the semantic variant of FTD, which is not the case here. 1. The behavioral variant of FTD often presents with marked personality changes while sparing language functions. 2. FTLD-TDP Type B is most consistent with bvFTD, especially in patients with C9orf72 mutations. 3. Differentiating TDP-43 subtypes can provide clues to the underlying genetic background. Recent neuropathological studies and genetic research have refined our understanding of FTLD-TDP subtypes. FTLD-TDP Type B is increasingly recognized as the pathology underlying bvFTD with preserved language, making it the most accurate choice in this scenario.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "LBD PET finding",
    "option_a": "(Occipital hypometabolism) is the correct FDG",
    "option_b": "\u2019s mention of 'Asymmetric parietal acsetic' is not a recognized pattern and likely a typographic error; parietal hypometabolism is more common in AD. Option C (Leigh syndrome) and Option D (Neurodegeneration with brain iron accumulation) refer to entirely different conditions with distinct imaging and clinical features.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Lewy Body Dementia (LBD) is a neurodegenerative disorder characterized by the presence of Lewy bodies\u2014abnormal aggregates of alpha\u2010synuclein\u2014in the brain. FDG-PET imaging is used to assess regional brain metabolism, which may aid in differentiating LBD from other dementias. In LBD, there is a distinct pattern of hypometabolism on FDG-PET, with the occipital lobes being preferentially affected. This occipital hypometabolism is thought to correlate with the pathology of alpha-synuclein deposition and explains associated visual hallucinations and visuospatial deficits. Patients with LBD often exhibit visual hallucinations, fluctuating cognition, and parkinsonian features. The occipital hypometabolism seen on PET correlates with these clinical manifestations and helps distinguish LBD from Alzheimer\u2019s disease, which typically shows parietal and temporoparietal hypometabolism. The diagnostic approach in suspected LBD includes clinical evaluation, neuropsychological testing, and neuroimaging. Differential diagnoses include Alzheimer\u2019s disease, where PET typically shows temporoparietal hypometabolism, and other atypical parkinsonian syndromes. FDG-PET plays a pivotal role in distinguishing these entities. Management of LBD involves symptomatic treatment. Cholinesterase inhibitors are often used to improve cognition and reduce hallucinations. Caution is exercised with antipsychotics because of neuroleptic sensitivity. In women of childbearing age or during lactation, non-pharmacologic interventions and careful selection of medications (with appropriate risk\u2013benefit discussions) are recommended since most standard therapies are used off-label or with caution in these populations. Option A (Occipital hypometabolism) is the correct FDG-PET finding in LBD. Option B\u2019s mention of 'Asymmetric parietal acsetic' is not a recognized pattern and likely a typographic error; parietal hypometabolism is more common in AD. Option C (Leigh syndrome) and Option D (Neurodegeneration with brain iron accumulation) refer to entirely different conditions with distinct imaging and clinical features. 1. Occipital hypometabolism on FDG-PET is a key imaging feature supporting a diagnosis of LBD. 2. Visual hallucinations and visuospatial deficits in LBD correlate with occipital involvement. 3. Differentiation from AD is crucial as management strategies differ significantly. Recent imaging studies and updated guidelines continue to validate occipital hypometabolism on FDG-PET as a characteristic and supportive biomarker for LBD. This pattern is now well incorporated into diagnostic criteria to help distinguish LBD from other dementias.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Female ataxia for one year, and mild cognitive impairment, ;MRI showed cerebellar peduncle hyperintensities no further details",
    "option_a": "(Paraneoplastic) is correct because the clinical picture of subacute ataxia, cerebellar peduncle hyperintensities, and cognitive impairment in a female patient is most consistent with paraneoplastic cerebellar degeneration. Option B (Prematuration fragile X syndrome) is incorrect: what is likely implied is FXTAS, a disorder seen predominantly in older males with different imaging and clinical features. Option C (Benign MS) is inappropriate here because MS usually presents with multifocal lesions and a pattern of relapses and remissions, not a steadily progressive course with the described features.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Paraneoplastic cerebellar degeneration is an immune\u2010mediated disorder in which the body\u2019s immune response to an underlying malignancy (often seen in middle\u2010aged women) cross-reacts with cerebellar tissue. This syndrome classically produces cerebellar ataxia and may be accompanied by cognitive impairment. MRI findings such as cerebellar peduncle hyperintensities add radiologic support to this diagnosis. The disease occurs when antibodies (e.g., anti-Yo, anti-Hu) produced in response to a neoplasm mistakenly target antigens expressed by cerebral neurons, especially within the Purkinje cells of the cerebellum. The resulting immune-mediated inflammation and neuronal damage lead to symptomatic ataxia and cognitive changes. Recent evidence emphasizes early detection of these antibodies for prompt cancer screening and immunotherapy. A female with a one-year history of ataxia and mild cognitive impairment fits the profile for a paraneoplastic syndrome. The subacute chronic progression and MRI evidence of cerebellar peduncle involvement further support the diagnosis, as such imaging changes are less characteristic of degenerative or demyelinating processes. The workup should include a thorough history and examination with attention to paraneoplastic syndromes, serum and cerebrospinal fluid antibody panels (e.g., anti-Yo), and cancer screening (mammography, pelvic ultrasound, CT scans) to locate an occult neoplasm. Differential diagnoses include FXTAS (typically in older males with MCP hyperintensities and intention tremor) and multiple sclerosis (which usually presents with multiple focal lesions and a relapsing\u2013remitting course). First-line management involves treating the underlying malignancy along with immunosuppressive therapies such as high-dose corticosteroids, IVIG, or plasmapheresis to reduce immune attack on neural tissue. A multidisciplinary approach is essential. In cases involving pregnancy or lactation, immunotherapies must be chosen carefully to avoid teratogenic risks while still controlling the neurological syndrome, often requiring coordinated care with obstetrics and oncology. Option A (Paraneoplastic) is correct because the clinical picture of subacute ataxia, cerebellar peduncle hyperintensities, and cognitive impairment in a female patient is most consistent with paraneoplastic cerebellar degeneration. Option B (Prematuration fragile X syndrome) is incorrect: what is likely implied is FXTAS, a disorder seen predominantly in older males with different imaging and clinical features. Option C (Benign MS) is inappropriate here because MS usually presents with multifocal lesions and a pattern of relapses and remissions, not a steadily progressive course with the described features. 1. Always consider paraneoplastic syndromes in unexplained subacute cerebellar degeneration, especially in middle-aged women. 2. MRI findings such as cerebellar peduncle hyperintensities can be a key radiologic clue. 3. Early paraneoplastic antibody testing leads to more effective screening for occult malignancies. Recent clinical guidelines stress the importance of recognizing paraneoplastic syndromes early to initiate cancer screening and immunotherapy promptly. Advances in antibody detection have improved diagnostic accuracy, and studies continue to explore optimal immunosuppressive strategies in this patient population.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Man with multiple cognitive domain involvement has ?ataxia & extra pyramidal, and pathology showing PrPsc amyloid plaque lived for 5 years, asking about type of prion disease",
    "option_a": "Fatal familial insomnia",
    "option_b": "Family CJD",
    "option_c": "vCJD",
    "option_d": "GSS",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Prion diseases are a group of neurodegenerative conditions caused by misfolded prion proteins. Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS) is a familial prion disorder characterized by a longer disease course compared to other prionopathies. GSS results from a mutation in the prion protein gene leading to the accumulation of misfolded PrPSc that aggregates into amyloid plaques. This misfolded protein disrupts normal neural function, predominantly affecting the cerebellum and basal ganglia, leading to ataxia, extrapyramidal signs, and cognitive decline. Neuropathologically, the presence of PrPSc amyloid plaques is a hallmark of GSS. The patient presents with involvement of multiple cognitive domains, ataxia, and extrapyramidal features, and notably, a prolonged disease course with a 5-year survival. Such a course is more characteristic of GSS than other prion diseases, which typically have rapid progressions. Definitive diagnosis involves a combination of clinical findings, family history, and genetic testing for prion protein gene mutations complemented by neuropathological examination. Differentials include sporadic CJD (rapidly progressive), fatal familial insomnia (characterized mainly by sleep disturbances), and variant CJD (associated with vCJD\u2019s unique psychiatric presentation and shorter course). There is no curative therapy for prion diseases. Management is supportive and symptomatic, focusing on palliative care and quality of life measures. In pregnant or lactating patients, supportive treatments remain the mainstay as no disease-modifying therapies are available and experimental interventions have not been proven safe. Option D (GSS) is correct because the 5-year disease course, association with PrPSc amyloid plaques, and the combination of ataxia, extrapyramidal signs, and cognitive impairment best fit GSS. Option A (Fatal familial insomnia) is incorrect due to its markedly prominent insomnia and autonomic dysfunction. Option B (Familial CJD) generally has a more rapid progression, and option C (variant CJD) has a different etiological link and clinical profile. 1. GSS is a familial prion disease with a notably protracted course. 2. Amyloid plaques on pathology confirm the diagnosis. 3. Genetic testing is crucial in patients with suspected familial prion disorders. Current research focuses on the molecular mechanisms of prion propagation with novel therapeutic agents under investigation. However, no effective treatment exists, and management remains predominantly supportive. Updated clinical guidelines emphasize accurate genetic counseling and symptomatic care in familial prion disorders.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Apathy is more seen in which condition?",
    "option_a": "TBI",
    "option_b": "FTD",
    "option_c": "IPD",
    "option_d": "Wilson",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Apathy is defined as a diminished initiative, motivation, and emotional expression, and is a common neuropsychiatric feature in various neurodegenerative disorders. It is particularly prominent in frontotemporal dementia (FTD), which primarily affects the frontal and temporal lobes. FTD is associated with degeneration of the frontal and anterior temporal brain regions, leading to impaired regulation of behavior and motivation. This is mediated by abnormal protein accumulations such as tau or TDP-43 that interfere with neuronal function and connection in these regions. FTD commonly presents in mid-to-late life with marked personality changes, disinhibition, and apathy. The presentation of apathy in the absence of significant emotional distress distinguishes FTD from other conditions like depression. Alternative causes, such as traumatic brain injury or Parkinson\u2019s disease, may show apathy but with different associated features. Diagnosis relies on a detailed neuropsychological assessment, neuroimaging (which often shows frontal and/or anterior temporal atrophy), and exclusion of other causes like depression or vascular dementia. Differential diagnoses include TBI (often with a clear history of injury) and Parkinson\u2019s disease (characterized by primary motor findings and other non-motor symptoms). Management of FTD is largely supportive. Nonpharmacologic interventions including behavioral therapy and caregiver support are essential. Pharmacologically, SSRIs or atypical antipsychotics may be used to manage behavioral symptoms, though none directly reverse apathy. In pregnant or lactating patients, the use of psychotropic medications must be cautiously evaluated against potential fetal or neonatal risks. Option B (FTD) is correct because apathy is a hallmark clinical feature of the behavioral variant of FTD. Option A (TBI) is less likely given the absence of a history of head trauma; Option C (IPD) may exhibit apathy but is primarily characterized by motor symptoms; Option D (Wilson\u2019s disease) typically presents with hepatic involvement, movement disorders, and psychiatric symptoms rather than pure apathy. 1. Apathy in FTD reflects frontal lobe dysfunction and is a key diagnostic feature. 2. Differentiating apathy from depression is critical as FTD is associated with a lack of self-initiative without accompanying sadness. 3. Neuroimaging may reveal frontal and temporal atrophy supporting the diagnosis. Recent studies in FTD have highlighted the value of biomarkers and advanced imaging in distinguishing it from other dementias. Current guidelines advocate for a multidisciplinary approach focused on symptomatic management and caregiver education.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "65 years old male with 2 years history of progressive decline in his cognitive especially memory domain. He has impaired ability to carry out the instrumental activities of daily life. ECG shows also first degree heart block. Typical scenario of Alzheimer. What is the best management option?",
    "option_a": "Refer to Cardiology",
    "option_b": "Start anti NMDA",
    "option_c": "Start ChE inhibitor",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is the most common neurodegenerative dementia, characterized predominantly by memory impairment with a gradual decline in cognitive and functional abilities. Cholinesterase inhibitors (ChEIs) are the standard first-line treatment for mild to moderate AD. AD is pathologically characterized by the formation of beta-amyloid plaques and neurofibrillary tangles composed of hyperphosphorylated tau proteins. This leads to the degeneration of synapses and neurons, particularly in the hippocampus and cortical regions, and accounts for the observed cognitive deficits. Although first-degree heart block may be noted incidentally, the cholinergic hypothesis behind cognitive decline remains the target for ChEIs. The patient\u2019s 2-year history of progressive memory decline affecting instrumental activities of daily living is typical for AD. The ECG finding of first-degree heart block requires caution but does not preclude the use of ChEIs, which target the cholinergic deficit and can modestly enhance cognitive function. The diagnosis of AD is largely clinical, supported by cognitive assessments (e.g., MMSE, MoCA) and neuroimaging (MRI showing medial temporal lobe atrophy). Differential diagnoses include vascular dementia (typically having a stepwise progression), frontotemporal dementia (more behavioral changes), and dementia with Lewy bodies (characterized by visual hallucinations and fluctuating cognition). For mild to moderate AD, first-line treatment is a cholinesterase inhibitor (e.g., donepezil, rivastigmine, or galantamine). When initiating ChEIs in patients with conduction abnormalities such as first-degree heart block, careful dose titration and cardiac monitoring are recommended. In the context of pregnancy or lactation\u2014though rare in AD\u2014risks and benefits must be critically evaluated since many AD medications are not typically used in these populations. Option C (Start ChE inhibitor) is correct because it aligns with the current standard of care for managing mild to moderate Alzheimer\u2019s disease. Option A (Refer to Cardiology) might be necessary for monitoring the heart block but does not address the primary cognitive decline. Option B (Start anti-NMDA) is incorrect as NMDA receptor antagonists like memantine are reserved for moderate to severe stages of AD and are not first-line in this scenario. 1. Cholinesterase inhibitors are first-line therapy for symptomatic management in mild to moderate Alzheimer\u2019s disease. 2. Always evaluate cardiac conduction when initiating ChEIs, as they may exacerbate bradycardia. 3. AD is primarily a clinical diagnosis supported by imaging and cognitive testing. Recent guidelines reaffirm the modest benefits of ChEIs in slowing cognitive decline in AD. Ongoing research into disease-modifying therapies, including amyloid and tau-based interventions, underscores the evolving treatment landscape, though none have yet supplanted current first-line agents.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the most common memory affected in Korsakoff's encephalopathy?",
    "option_a": "Episodic memory",
    "option_b": "Declarative",
    "option_c": "Working",
    "option_d": "Semantic",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Korsakoff's encephalopathy is a neuropsychiatric syndrome most often seen in chronic alcoholics resulting from thiamine (vitamin B1) deficiency. The core issue is an inability to properly form and retrieve new memories\u2014especially episodic memories. Thiamine deficiency leads to degeneration in diencephalic structures such as the mammillary bodies and mediodorsal thalamic nuclei. These areas are crucial for the consolidation of episodic memory, and their damage impairs the transfer of information from short-term to long-term storage. Current evidence supports that early thiamine repletion is essential to limit these structural changes. Patients with Korsakoff's encephalopathy typically present with anterograde amnesia (difficulty forming new episodic memories) along with confabulation. Other aspects of memory, such as immediate recall and procedural memory, are less affected. The marked impairment of episodic memory distinguishes it from other memory domains like semantic or working memory. Diagnosis is largely clinical and is based on the patient\u2019s history (often chronic alcohol misuse), nutritional status, and neurological exam. Neuroimaging (MRI) may reveal signal abnormalities in the mammillary bodies and thalamus. Differential diagnoses include Alzheimer\u2019s disease (which typically affects multiple memory domains in older individuals) and other forms of dementia, but the acute history with nutritional deficiency strongly favors Korsakoff's encephalopathy. The primary treatment is immediate high\u2010dose parenteral thiamine replacement. Early intervention can halt progression and may reverse some acute symptoms. In pregnant or lactating patients, thiamine supplementation remains essential and is considered safe, with careful monitoring of dosing to prevent fetal or neonatal complications. Option A (Episodic memory) is correct because Korsakoff's encephalopathy most commonly disrupts the ability to form new episodic memories. Option B (Declarative memory) is too broad, as it includes both episodic and semantic memory. Option C (Working memory) is typically preserved, and Option D (Semantic memory) is comparatively less affected. \u2022 Confabulation is a common clinical finding. \u2022 Early thiamine treatment is key to preventing irreversible damage. \u2022 Episodic memory loss is the hallmark of Korsakoff's encephalopathy. Recent clinical guidelines emphasize early recognition and high-dose thiamine administration, as well as the use of MRI to detect associated structural changes. Studies continue to explore neuroprotective strategies that might further limit progression.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]